Tacrolimus toxicity in organ transplantation: an overview
Archives of Medical Laboratory Sciences,
Vol. 3 No. 3 (2017),
13 May 2018
https://doi.org/10.22037/amls.v3i3.20832
Abstract
Tacrolimus is a macrolide lactone antibiotic, and acts as a calcineurin inhibitor. It is widely used to prevent organ transplant rejection. It has been approved as first-line treatment after organ transplantation. Tacrolimus has narrow therapeutic range and wide individual variability in its pharmacokinetics. In organ transplantation, immunosuppression is associated with important risks, in particular, related to infections and cardiovascular diseases, which are the predominant causes of death in those with a functioning graft. This review focuses on toxicity of tacrolimus after transplantation. Tacrolimus toxicity is a major determinant of morbidity and mortality in organ recipients after transplantation. Therefore, reducing toxicities has become a priority. To decrease the incidence of side effects, and expand graft survival, the appropriate initial and maintenance dose of tacrolimus is essential. Clinical conditions that influence tacrolimus pharmacokinetics, such as hemorrhage, systemic inflammation and shock, all result in higher variations of tacrolimus concentrations. In addition, unbound plasma concentration is a major important reasonable parameter for monitoring of receiving optimal tacrolimus dosing in the unstable patient. Therefore, the approach of tacrolimus monitoring is vital and will support to avoid tacrolimus toxicity in the early days after transplantation.
- Tacrolimus
- Organ transplantation
- Toxicity
- Tacrolimus monitoring
How to Cite
References
Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. Journal Antibiot. 1987;40(9):1249-55.
Group EFMLS. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet. 1994;344(8920):423-8.
Group UMFLS. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med. 1994;1994(331):1110-5.
Spencer CM, Goa KL, Gillis JC. Tacrolimus. Drugs. 1997;54(6):925-75.
Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29(6):404-30.
Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation. 1996;62(7):920-6.
Van Duijnhoven E, Christiaans M, Undre N, Stevenson P, Van Hooff J, editors. The effect of breakfast on the oral bioavailability of tacrolimus in diabetic and nondiabetic patients before transplantation. Transplant Proc. 1998;30(4):1268-70.
Rusnak F, Mertz P. Calcineurin: form and function. Physiol Rev. 2000;80(4):1483-521.
Sikma M, van Maarseveen E, van de Graaf E, Kirkels J, Verhaar M, Donker D, et al. Pharmacokinetics and toxicity of tacrolimus early after heart and lung transplantation. Am J Transplant. 2015;15(9):2301-13.
Masuda S, Uemoto S, Hashida T, Inomata Y, Tanaka K, Inui Ki. Effect of intestinal P‐glycoprotein on daily tacrolimus trough level in a living‐donor small bowel recipient. Clin Pharmacol Ther. 2000;68(1):98-103.
Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993;268(9):6077-80.
Roy JN, Barama A, Poirier C, Vinet B, Roger M. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics. 2006;16(9):659-65.
Liptak P, Ivanyi B. Primer: histopathology of calcineurin-inhibitor toxicity in renal allografts. Nat Clin Pract Nephrol. 2006;2(7):398-404.
Hammerstrom AE, Howell J, Gulbis A, Rondon G, Champlin RE, Popat U. Tacrolimus‐associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation. Am JHematol. 2013;88(4):301-5.
Long C, Cook LG, Hamilton SL, Wu G-Y, Mitchell BM. FK506 binding protein 12/12.6 depletion increases endothelial nitric oxide synthase threonine 495 phosphorylation and blood pressure. Hypertension. 2007;49(3):569-76.
Dehghani SM, Haghighat M, Imanieh MH, Zahmatkeshan M, Borzooei M, Amoozegar H, et al. Tacrolimus related hypertrophic cardiomyopathy in liver transplant recipients. Arch Iran Med. 2010;13(2):116.
Palepu S, Prasad G. New-onset diabetes mellitus after kidney transplantation: Current status and future directions. World J Diabetes. 2015;6(3):445.
Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4(2):481-508.
Platz K-P, Mueller AR, Blumhardt G, Bachmann S, Bechstein W-O, Kahl A, et al. Nephrotoxicity folloeing orthotopic liver transplantation. Transplantation. 1994;58(2):170-8.
Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, et al., editors. Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation. Mayo Clin Proc. 1994;69(2):105-11.
Keenan RJ, Konishi H, Kawai A, Paradis IL, Nunley DR, Iacono AT, et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg. 1995;60(3):580-5.
Armitage JM, Kormos RL, Morita S, Fung J, Marrone GC, Hardesty RL, et al. Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. Ann Thorac Surg. 1992;54(2):205-11.
Wu S-Y, Chen T-W, Feng A-C, Fan H-L, Hsieh C-B, Chung K-P. Comprehensive risk assessment for early neurologic complications after liver transplantation. World J Gastroenterol. 2016;22(24):5548.
Zegarska J, Hryniewiecka E, Zochowska D, Samborowska E, Jazwiec R, Borowiec A, et al., editors. Tacrolimus Metabolite M-III May Have Nephrotoxic and Myelotoxic Effects and Increase the Incidence of Infections in Kidney Transplant Recipients. Transplant Proc.2016 ;48(5):1539-42.
Song T, Rao Z, Tan Q, Qiu Y, Liu J, Huang Z, et al. Calcineurin Inhibitors Associated Posterior Reversible Encephalopathy Syndrome in Solid Organ Transplantation: Report of 2 Cases and Literature Review. Medicine. 2016;95(14):e3173.
Wijdicks EF. Neurotoxicity of immunosuppressive drugs. Liver Transpl. 2001;7(11):937-42.
Feske SK. Posterior reversible encephalopathy syndrome: a review. Seminars in neurology. Semin Neurol. 2011;31(2):202-15.
Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010;85(5):427-32.
Bartynski W. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. Am J Neuroradiol. 2008;29(6):1043-9.
Wu Q, Marescaux C, Wolff V, Jeung M-Y, Kessler R, Lauer V, et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation. Eur Neurol. 2010;64(3):169-77.
Yamauchi A, Ieiri I, Kataoka Y, Tanabe M, Nishizaki T, Oishi R, et al. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation. 2002;74(4):571-2.
Yanagimachi M, Naruto T, Tanoshima R, Kato H, Yokosuka T, Kajiwara R, et al. Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor‐related neurotoxicity after hematopoietic stem cell transplantation. Clin Transplant. 2010;24(6):855-61.
Szyguła-Jurkiewicz B, Szczurek W, Gąsior M, Zembala M. Risk factors of cardiac allograft vasculopathy. Kardiochir Torakochirurgia Pol. 2015;12(4):328-33.
Zbroch E, Małyszko J, Myśliwiec M, Przybyłowski P, Durlik M. Hypertension in solid organ transplant recipients. Ann Transplant. 2011;17(1):100-7.
Dharmashankar K, Widlansky ME. Vascular endothelial function and hypertension: insights and directions. Curr Hypertens Rep. 2010;12(6):448-55.
De Lima JJ, Xue H, Coburn L, Andoh TF, Mccarron DA, Bennett WM, et al. Effects of FK506 in rat and human resistance arteries. Kidney Int. 1999;55(4):1518-27.
Takeda Y, Miyamori I, Furukawa K, Inaba S, Mabuchi H. Mechanisms of FK 506–Induced Hypertension in the Rat. Hypertension. 1999;33(1):130-6.
Cook LG, Chiasson VL, Long C, Wu G-Y, Mitchell BM. Tacrolimus reduces nitric oxide synthase function by binding to FKBP rather than by its calcineurin effect. Kidney Int. 2009;75(7):719-26.
Xin H-B, Senbonmatsu T, Cheng D-S, Wang Y-X, Copello JA, Ji G-J, et al. Oestrogen protects FKBP12. 6 null mice from cardiac hypertrophy. Nature. 2002;416(6878):334-8.
Chiasson VL, Talreja D, Young KJ, Chatterjee P, Banes-Berceli AK, Mitchell BM. FK506 binding protein 12 deficiency in endothelial and hematopoietic cells decreases regulatory T cells and causes hypertension. Hypertension. 2011;57(6):1167-75.
Amador FJ, Stathopulos PB, Enomoto M, Ikura M. Ryanodine receptor calcium release channels: lessons from structure–function studies. FEBS J. 2013;280(21):5456-70.
Missiaen L, Robberecht W, Van Den Bosch L, Callewaert G, Parys J, Wuytack F, et al. Abnormal intracellular Ca 2+ homeostasis and disease. Cell calcium. 2000;28(1):1-21.
Thiru S, Collier D, Calne R, editors. Pathological studies in canine and baboon renal allograft recipients immunosuppressed with FK-506. Transplant Proc. 1987;19(5): 98-9.
Mano A, Nakatani T, Yahata Y, Kato T, Hashimoto S, Wada K, et al., editors. Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient: case report. Transplant Proc. 2009;41(9):3831-4.
Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29(8):914-56.
Pham P, Pham P, Pham SV, Pham P, Pham P. New onset diabetes after transplantation (NODAT): an overview. Diabetes Metab Syndr Obes. 2011;4:175-86.
Pereira MJ, Palming J, Rizell M, Aureliano M, Carvalho E, Svensson MK, et al. Cyclosporine A and tacrolimus reduce the amount of GLUT4 at the cell surface in human adipocytes: increased endocytosis as a potential mechanism for the diabetogenic effects of immunosuppressive agents. J Clin Endocrinol Metab. 2014;99(10):E1885-94.
Brewer PD, Habtemichael EN, Romenskaia I, Mastick CC, Coster AC. Insulin-regulated Glut4 Translocation: membrane protein trafficking with six distinctive steps. J Biol Chem. 2014;289(25):17280-98.
Radu RG, Fujimoto S, Mukai E, Takehiro M, Shimono D, Nabe K, et al. Tacrolimus suppresses glucose-induced insulin release from pancreatic islets by reducing glucokinase activity. Am J PhysiolEndocrinol Metab. 2005;288(2):E365-71.
Aali E, Mirzamohammadi S, Ghaznavi H, Madjd Z, Larijani B, Rayegan S, Sharifi AM. A comparative study of mesenchymal stem cell transplantation with its paracrine effect on control of hyperglycemia in type 1 diabetic rats. J Diabetes Metab Disord. 2014;13(1):76.
Mirzamohammadi S, Aali E, Najafi R, Kamarul T, Mehrabani M, Aminzadeh A, Sharifi AM. Effect of 17β-estradiol on mediators involved in mesenchymal stromal cell trafficking in cell therapy of diabetes. Cytotherapy. 2015;17(1):46-57.
Aminzadeh A. Protective effect of tropisetron on high glucose induced apoptosisand oxidative stress in PC12 cells: roles of JNK, P38 MAPKs,and mitochondria pathway. MetBrainDis. 2017;32(3):819-26.
Rayegan S, Dehpour AR, Sharifi AM. Studying neuroprotective effect of Atorvastatin as a small molecule drug on high glucose-induced neurotoxicity in undifferentiated PC12 cells: role of NADPH oxidase. Metab Brain Dis. 2017;32(1):41-49.
Shapiro R, Scantlebury V, Jordan M, Vivas C, Gritsch H, McCauley J, et al. Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature. Transplant Proc. 1997;29(6):2737-8.
Yasuhara M, Hashida T, Toraguchi M, Hashimoto Y, Kimura M, Hori R, et al. Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. Transplant proc. 1995;27(1):1108-10.
Tsunoda SM, Aweeka FT. The use of therapeutic drug monitoring to optimise immunosuppressive therapy. Clin Pharmacokinet. 1996;30(2):107-40.
- Abstract Viewed: 459 times
- PDF Downloaded: 224 times